Mesoblast (MESO) Non-Current Deffered Revenue (2015 - 2026)
Mesoblast (MESO) posted Non-Current Deffered Revenue of $2.5 million for Q4 2025, little changed sequentially from $2.5 million in Q2 2025, and little changed YoY from $2.5 million in Q4 2024.
Analysis
Mesoblast (MESO) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
Mesoblast has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $2.5 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was little changed at $2.5 million in Q4 2025 per MESO's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $91.6 million in Q4 2022 and troughed at $2.5 million in Q1 2021.
- A 5-year average of $8.4 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 3564.68% in 2022, then tumbled 97.27% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2021, then soared by 3564.68% to $91.6 million in 2022, then sank by 97.27% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 2.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 2.50 Mn |
| Jun 30, 2020 | 2.50 Mn |
| Mar 31, 2020 | 2.50 Mn |